CN112114126B - Diagnostic marker for systemic lupus erythematosus and application thereof - Google Patents
Diagnostic marker for systemic lupus erythematosus and application thereof Download PDFInfo
- Publication number
- CN112114126B CN112114126B CN202010813838.8A CN202010813838A CN112114126B CN 112114126 B CN112114126 B CN 112114126B CN 202010813838 A CN202010813838 A CN 202010813838A CN 112114126 B CN112114126 B CN 112114126B
- Authority
- CN
- China
- Prior art keywords
- leu
- ser
- val
- ala
- pro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/104—Lupus erythematosus [SLE]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a diagnostic marker of systemic lupus erythematosus and application thereof, relates to the technical field of biomedical detection, and discloses that a semaphorin 4A (Sema 4A) membrane bound type and a soluble type have higher diagnostic efficacy on systemic lupus erythematosus patients, can be used for evaluating disease state activity and organ injury, and can well identify the systemic lupus erythematosus and rheumatoid arthritis, so that the Sema4A can be used as the diagnostic marker of the systemic lupus erythematosus. And the Sema4A has higher sensitivity to the systemic lupus erythematosus, and the detection of the Sema4A and the autoantibody is helpful for improving the detection rate of the early stage of the disease, which makes up the defect of low diagnosis sensitivity of the current clinical laboratory to a certain extent.
Description
Technical Field
The invention belongs to the technical field of biomedical detection, and particularly relates to a diagnostic marker for systemic lupus erythematosus and application thereof.
Background
Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by the production of autoantibodies against nuclear components and the appearance of multiple clinical manifestations from multiple systemic, multiple organ involvement. SLE is clinically manifested in complex and diverse forms with atypical early symptoms, leading to difficulties in early diagnosis of the disease.
Diagnosis of SLE requires a combination of patient symptoms, physical examination, and laboratory examination. However, the early clinical manifestations of SLE are atypical, and the high-efficiency and accurate laboratory detection indexes become important diagnosis bases for early diseases. Currently, common laboratory diagnostic indicators for SLE include Antinuclear Antibodies (ANA) and extractable nuclear antigen Antibodies (ENA), such as pathogenic to extracellular nuclear antigen Antibodies (Antibodies), anti-dsDNA Antibodies (Antibodies), and characteristic Antibodies, anti-Sm Antibodies (Antibodies). These antibodies all have high specificity for SLE, but their sensitivity is low, leading to a high rate of missed diagnosis in early SLE patients.
In addition, some patients with SLE have finger joint swelling pain as the first symptom, while patients with RA have joint symptoms as the main clinical manifestation. Meanwhile, ANA positive, RF positive, ESR and CRP increase can be generated in both laboratory tests, so that the ANA positive, the RF positive, the ESR and the CRP increase are difficult to distinguish. There is therefore a continuing need to find new diagnostic markers to meet the clinical needs of early disease diagnosis, disease assessment and efficacy monitoring.
Disclosure of Invention
The invention aims to: aiming at the problems that indexes for SLE diagnosis in the prior art are low in sensitivity and easy to cause missed detection, the invention provides a high-sensitivity systemic lupus erythematosus diagnostic marker and application thereof.
The technical scheme adopted by the invention is as follows:
a diagnostic marker of systemic lupus erythematosus, the amino acid sequence of the diagnostic marker is shown as SEQ ID NO:1 to SEQ ID NO: 4; the specific sequence is as follows:
SEQ ID NO：1
MetAlaLeuProAlaLeuGlyLeuAspProTrpSerLeuLeuGlyLeuPheLeuPheGlnLeuLeuGlnLeuLeuLeuProThrThrThrAlaGlyGlyGlyGlyGlnGlyProMetProArgValArgTyrTyrAlaGlyAspGluArgArgAlaLeuSerPhePheHisGlnLysGlyLeuGlnAspPheAspThrLeuLeuLeuSerGlyAspGlyAsnThrLeuTyrValGlyAlaArgGluAlaIleLeuAlaLeuAspIleGlnAspProGlyValProArgLeuLysAsnMetIleProTrpProAlaSerAspArgLysLysSerGluCysAlaPheLysLysLysSerAsnGluThrGlnCysPheAsnPheIleArgValLeuValSerTyrAsnValThrHisLeuTyrThrCysGlyThrPheAlaPheSerProAlaCysThrPheIleGluLeuGlnAspSerTyrLeuLeuProIleSerGluAspLysValMetGluGlyLysGlyGlnSerProPheAspProAlaHisLysHisThrAlaValLeuValAspGlyMetLeuTyrSerGlyThrMetAsnAsnPheLeuGlySerGluProIleLeuMetArgThrLeuGlySerGlnProValLeuLysThrAspAsnPheLeuArgTrpLeuHisHisAspAlaSerPheValAlaAlaIleProSerThrGlnValValTyrPhePhePheGluGluThrAlaSerGluPheAspPhePheGluArgLeuHisThrSerArgValAlaArgValCysLysAsnAspValGlyGlyGluLysLeuLeuGlnLysLysTrpThrThrPheLeuLysAlaGlnLeuLeuCysThrGlnProGlyGlnLeuProPheAsnValIleArgHisAlaValLeuLeuProAlaAspSerProThrAlaProHisIleTyrAlaValPheThrSerGlnTrpGlnValGlyGlyThrArgSerSerAlaValCysAlaPheSerLeuLeuAspIleGluArgValPheLysGlyLysTyrLysGluLeuAsnLysGluThrSerArgTrpThrThrTyrArgGlyProGluThrAsnProArgProGlySerCysSerValGlyProSerSerAspLysAlaLeuThrPheMetLysAspHisPheLeuMetAspGluGlnValValGlyThrProLeuLeuValLysSerGlyValGluTyrThrArgLeuAlaValGluThrAlaGlnGlyLeuAspGlyHisSerHisLeuValMetTyrLeuGlyThrThrThrGlySerLeuHisLysAlaValValSerGlyAspSerSerAlaHisLeuValGluGluIleGlnLeuPheProAspProGluProValArgAsnLeuGlnLeuAlaProThrGlnGlyAlaValPheValGlyPheSerGlyGlyValTrpArgValProArgAlaAsnCysSerValTyrGluSerCysValAspCysValLeuAlaArgAspProHisCysAlaTrpAspProGluSerArgThrCysCysLeuLeuSerAlaProAsnLeuAsnSerTrpLysGlnAspMetGluArgGlyAsnProGluTrpAlaCysAlaSerGlyProMetSerArgSerLeuArgProGlnSerArgProGlnIleIleLysGluValLeuAlaValProAsnSerIleLeuGluLeuProCysProHisLeuSerAlaLeuAlaSerTyrTyrTrpSerHisGlyProAlaAlaValProGluAlaSerSerThrValTyrAsnGlySerLeuLeuLeuIleValGlnAspGlyValGlyGlyLeuTyrGlnCysTrpAlaThrGluAsnGlyPheSerTyrProValIleSerTyrTrpValAspSerGlnAspGlnThrLeuAlaLeuAspProGluLeuAlaGlyIleProArgGluHisValLysValProLeuThrArgValSerGlyGlyAlaAlaLeuAlaAlaGlnGlnSerTyrTrpProHisPheValThrValThrValLeuPheAlaLeuValLeuSerGlyAlaLeuIleIleLeuValAlaSerProLeuArgAlaLeuArgAlaArgGlyLysValGlnGlyCysGluThrLeuArgProGlyGluLysAlaProLeuSerArgGluGlnHisLeuGlnSerProLysGluCysArgThrSerAlaSerAspValAspAlaAspAsnAsnCysLeuGlyThrGluValAla
SEQ ID NO：2
MetIleProTrpProAlaSerAspArgLysLysSerGluCysAlaPheLysLysLysSerAsnGluGluLeuGlnAspSerTyrLeuLeuProIleSerGluAspLysValMetGluGlyLysGlyGlnSerProPheAspProAlaHisLysHisThrAlaValLeuValAspGlyMetLeuTyrSerGlyThrMetAsnAsnPheLeuGlySerGluProIleLeuMetArgThrLeuGlySerGlnProValLeuLysThrAspAsnPheLeuArgTrpLeuHisHisAspAlaSerPheValAlaAlaIleProSerThrGlnValValTyrPhePhePheGluGluThrAlaSerGluPheAspPhePheGluArgLeuHisThrSerArgValAlaArgValCysLysAsnAspValGlyGlyGluLysLeuLeuGlnLysLysTrpThrThrPheLeuLysAlaGlnLeuLeuCysThrGlnProGlyGlnLeuProPheAsnValIleArgHisAlaValLeuLeuProAlaAspSerProThrAlaProHisIleTyrAlaValPheThrSerGlnTrpGlnValGlyGlyThrArgSerSerAlaValCysAlaPheSerLeuLeuAspIleGluArgValPheLysGlyLysTyrLysGluLeuAsnLysGluThrSerArgTrpThrThrTyrArgGlyProGluThrAsnProArgProGlySerCysSerValGlyProSerSerAspLysAlaLeuThrPheMetLysAspHisPheLeuMetAspGluGlnValValGlyThrProLeuLeuValLysSerGlyValGluTyrThrArgLeuAlaValGluThrAlaGlnGlyLeuAspGlyHisSerHisLeuValMetTyrLeuGlyThrThrThrGlySerLeuHisLysAlaValValSerGlyAspSerSerAlaHisLeuValGluGluIleGlnLeuPheProAspProGluProValArgAsnLeuGlnLeuAlaProThrGlnGlyAlaValPheValGlyPheSerGlyGlyValTrpArgValProArgAlaAsnCysSerValTyrGluSerCysValAspCysValLeuAlaArgAspProHisCysAlaTrpAspProGluSerArgThrCysCysLeuLeuSerAlaProAsnLeuAsnSerTrpLysGlnAspMetGluArgGlyAsnProGluTrpAlaCysAlaSerGlyProMetSerArgSerLeuArgProGlnSerArgProGlnIleIleLysGluValLeuAlaValProAsnSerIleLeuGluLeuProCysProHisLeuSerAlaLeuAlaSerTyrTyrTrpSerHisGlyProAlaAlaValProGluAlaSerSerThrValTyrAsnGlySerLeuLeuLeuIleValGlnAspGlyValGlyGlyLeuTyrGlnCysTrpAlaThrGluAsnGlyPheSerTyrProValIleSerTyrTrpValAspSerGlnAspGlnThrLeuAlaLeuAspProGluLeuAlaGlyIleProArgGluHisValLysValProLeuThrArgValSerGlyGlyAlaAlaLeuAlaAlaGlnGlnSerTyrTrpProHisPheValThrValThrValLeuPheAlaLeuValLeuSerGlyAlaLeuIleIleLeuValAlaSerProLeuArgAlaLeuArgAlaArgGlyLysValGlnGlyCysGluThrLeuArgProGlyGluLysAlaProLeuSerArgGluGlnHisLeuGlnSerProLysGluCysArgThrSerAlaSerAspValAspAlaAspAsnAsnCysLeuGlyThrGluValAla
SEQ ID NO：3
MetIleProTrpProAlaSerAspArgLysLysSerGluCysAlaPheLysLysLysSerAsnGluThrGlnCysPheAsnPheIleArgValLeuValSerTyrAsnValThrHisLeuTyrThrCysGlyThrPheAlaPheSerProAlaCysThrPheIleGluLeuGlnAspSerTyrLeuLeuProIleSerGluAspLysValMetGluGlyLysGlyGlnSerProPheAspProAlaHisLysHisThrAlaValLeuValAspGlyMetLeuTyrSerGlyThrMetAsnAsnPheLeuGlySerGluProIleLeuMetArgThrLeuGlySerGlnProValLeuLysThrAspAsnPheLeuArgTrpLeuHisHisAspAlaSerPheValAlaAlaIleProSerThrGlnValValTyrPhePhePheGluGluThrAlaSerGluPheAspPhePheGluArgLeuHisThrSerArgValAlaArgValCysLysAsnAspValGlyGlyGluLysLeuLeuGlnLysLysTrpThrThrPheLeuLysAlaGlnLeuLeuCysThrGlnProGlyGlnLeuProPheAsnValIleArgHisAlaValLeuLeuProAlaAspSerProThrAlaProHisIleTyrAlaValPheThrSerGlnTrpGlnValGlyGlyThrArgSerSerAlaValCysAlaPheSerLeuLeuAspIleGluArgValPheLysGlyLysTyrLysGluLeuAsnLysGluThrSerArgTrpThrThrTyrArgGlyProGluThrAsnProArgProGlySerCysSerValGlyProSerSerAspLysAlaLeuThrPheMetLysAspHisPheLeuMetAspGluGlnValValGlyThrProLeuLeuValLysSerGlyValGluTyrThrArgLeuAlaValGluThrAlaGlnGlyLeuAspGlyHisSerHisLeuValMetTyrLeuGlyThrThrThrGlySerLeuHisLysAlaValValSerGlyAspSerSerAlaHisLeuValGluGluIleGlnLeuPheProAspProGluProValArgAsnLeuGlnLeuAlaProThrGlnGlyAlaValPheValGlyPheSerGlyGlyValTrpArgValProArgAlaAsnCysSerValTyrGluSerCysValAspCysValLeuAlaArgAspProHisCysAlaTrpAspProGluSerArgThrCysCysLeuLeuSerAlaProAsnLeuAsnSerTrpLysGlnAspMetGluArgGlyAsnProGluTrpAlaCysAlaSerGlyProMetSerArgSerLeuArgProGlnSerArgProGlnIleIleLysGluValLeuAlaValProAsnSerIleLeuGluLeuProCysProHisLeuSerAlaLeuAlaSerTyrTyrTrpSerHisGlyProAlaAlaValProGluAlaSerSerThrValTyrAsnGlySerLeuLeuLeuIleValGlnAspGlyValGlyGlyLeuTyrGlnCysTrpAlaThrGluAsnGlyPheSerTyrProValIleSerTyrTrpValAspSerGlnAspGlnThrLeuAlaLeuAspProGluLeuAlaGlyIleProArgGluHisValLysValProLeuThrArgValSerGlyGlyAlaAlaLeuAlaAlaGlnGlnSerTyrTrpProHisPheValThrValThrValLeuPheAlaLeuValLeuSerGlyAlaLeuIleIleLeuValAlaSerProLeuArgAlaLeuArgAlaArgGlyLysValGlnGlyCysGluThrLeuArgProGlyGluLysAlaProLeuSerArgGluGlnHisLeuGlnSerProLysGluCysArgThrSerAlaSerAspValAspAlaAspAsnAsnCysLeuGlyThrGluValAla
SEQ ID NO：4
MetGluGlyLysGlyGlnSerProPheAspProAlaHisLysHisThrAlaValLeuValAspGlyMetLeuTyrSerGlyThrMetAsnAsnPheLeuGlySerGluProIleLeuMetArgThrLeuGlySerGlnProValLeuLysThrAspAsnPheLeuArgTrpLeuHisHisAspAlaSerPheValAlaAlaIleProSerThrGlnValValTyrPhePhePheGluGluThrAlaSerGluPheAspPhePheGluArgLeuHisThrSerArgValAlaArgValCysLysAsnAspValGlyGlyGluLysLeuLeuGlnLysLysTrpThrThrPheLeuLysAlaGlnLeuLeuCysThrGlnProGlyGlnLeuProPheAsnValIleArgHisAlaValLeuLeuProAlaAspSerProThrAlaProHisIleTyrAlaValPheThrSerGlnTrpGlnValGlyGlyThrArgSerSerAlaValCysAlaPheSerLeuLeuAspIleGluArgValPheLysGlyLysTyrLysGluLeuAsnLysGluThrSerArgTrpThrThrTyrArgGlyProGluThrAsnProArgProGlySerCysSerValGlyProSerSerAspLysAlaLeuThrPheMetLysAspHisPheLeuMetAspGluGlnValValGlyThrProLeuLeuValLysSerGlyValGluTyrThrArgLeuAlaValGluThrAlaGlnGlyLeuAspGlyHisSerHisLeuValMetTyrLeuGlyThrThrThrGlySerLeuHisLysAlaValValSerGlyAspSerSerAlaHisLeuValGluGluIleGlnLeuPheProAspProGluProValArgAsnLeuGlnLeuAlaProThrGlnGlyAlaValPheValGlyPheSerGlyGlyValTrpArgValProArgAlaAsnCysSerValTyrGluSerCysValAspCysValLeuAlaArgAspProHisCysAlaTrpAspProGluSerArgThrCysCysLeuLeuSerAlaProAsnLeuAsnSerTrpLysGlnAspMetGluArgGlyAsnProGluTrpAlaCysAlaSerGlyProMetSerArgSerLeuArgProGlnSerArgProGlnIleIleLysGluValLeuAlaValProAsnSerIleLeuGluLeuProCysProHisLeuSerAlaLeuAlaSerTyrTyrTrpSerHisGlyProAlaAlaValProGluAlaSerSerThrValTyrAsnGlySerLeuLeuLeuIleValGlnAspGlyValGlyGlyLeuTyrGlnCysTrpAlaThrGluAsnGlyPheSerTyrProValIleSerTyrTrpValAspSerGlnAspGlnThrLeuAlaLeuAspProGluLeuAlaGlyIleProArgGluHisValLysValProLeuThrArgValSerGlyGlyAlaAlaLeuAlaAlaGlnGlnSerTyrTrpProHisPheValThrValThrValLeuPheAlaLeuValLeuSerGlyAlaLeuIleIleLeuValAlaSerProLeuArgAlaLeuArgAlaArgGlyLysValGlnGlyCysGluThrLeuArgProGlyGluLysAlaProLeuSerArgGluGlnHisLeuGlnSerProLysGluCysArgThrSerAlaSerAspValAspAlaAspAsnAsnCysLeuGlyThrGluValAla
further, the amino acid sequence of the marker is the amino acid sequence of SEQ ID NO:1 to SEQ ID NO:4 can express the same function after replacing, deleting and/or replacing one or more bases.
The application of the diagnosis marker in preparing a preparation for detecting systemic lupus erythematosus.
An agent comprising an antibody that specifically binds to the diagnostic marker.
A kit for detecting systemic lupus erythematosus, comprising an antibody capable of specifically binding to the diagnostic marker.
Semaphorin (semaphorin) is a large class of membrane-bound or secreted glycoprotein molecules that have important regulatory roles in a variety of physiological processes, including neurite guidance, vascular growth, bone resorption and remodeling, immunoregulation, and cardiac development. Semaphorins can be divided into 7 classes, with semaphorins from classes 1 and 2 being expressed only in invertebrates, semaphorins from classes 3, 4, 6 and 7 being expressed only in vertebrates, and semaphorins from class 5 being expressed in both. Studies show that semaphorin is widely involved in immune function regulation, can induce maturation and migration of DCs, regulate activation, proliferation and differentiation of T, B cells, and promote generation of inflammatory cytokines. The 4 th-class semaphorin has A, B, C, D subtypes, and Sema4A (including membrane bound and soluble) is found to have important value in the clinical diagnosis of SLE through research.
In the invention, when the membrane-bound Sema4A is taken as a diagnostic marker, the expression of the membrane-bound Sema4A on peripheral blood cells is analyzed by Flow Cytometry (FCM), and the specific steps are as follows:
(1) Collecting a peripheral blood sample;
(2) Adding peripheral blood samples into 4 centrifugal tubes of 5ml, and respectively naming the samples as a No. 1 centrifugal tube, a No. 2 centrifugal tube, a No. 3 centrifugal tube and a No. 4 centrifugal tube;
(3) Adding an anti-human CD100-Alexa 647 antibody, an anti-human CD4-PE antibody and an anti-human CD19-FITC antibody into a No. 1 centrifugal tube, and incubating at room temperature in a dark place for 15min; no. 3 centrifuge tube is provided with isotype control; adding an anti-human Sema4A-PerCP-eFluor 710 antibody, an anti-human CD11c-APC antibody, an anti-human CD4-PE antibody and an anti-human CD19-FITC antibody into a No. 2 centrifugal tube, incubating for 15min at room temperature in a dark place, and setting isotype control in the No. 4 centrifugal tube;
(4) Adding erythrocyte lysate into each centrifuge tube, and standing in the dark for 10min until the erythrocytes are completely lysed;
(5) Adding PBS into each tube, mixing uniformly, centrifuging, removing supernatant, and repeating twice;
(6) And (6) performing detection on the machine.
In the invention, when soluble Sema4A is taken as a diagnostic marker, enzyme-linked immunosorbent assay (ELISA) is adopted to detect the concentration of soluble Sema4A in plasma, and the specific steps are as follows:
(1) Preparing a reagent: (1) preparing a standard substance: taking out the Sema4A antibody standard substance from the ELISA kit, centrifuging, dissolving with 1ml of sample diluent, and fully and uniformly mixing to obtain a standard substance S7; then, 7 1.5ml Ep tubes (named as S0-S6 respectively) are sequentially arranged, 250pl sample diluent is added respectively, 250ml S7 standard substance is absorbed and placed in the first Ep tube (S6), 250ml is absorbed from the S6 and placed in the second Ep tube (S5), the standard substance is diluted by times in the same way, and S0 is the sample diluent; (2) preparing a washing working solution: the concentrated wash was washed with deionized water as follows: diluting by 25 times for later use; (3) preparing a biotin labeled antibody working solution: the biotin labeled antibody fluid was expressed as 1: diluting with 100 times of biotin labeled antibody diluent for later use; (4) preparing a horse radish peroxidase labeled avidin working solution: horse radish peroxidase-labeled avidin was added as 1: diluting 100 times with horse radish peroxidase labeled avidin diluent for later use;
(2) The following operations were performed according to the ELISA instructions:
(1) placing various reagents at room temperature for balancing for at least 30min, and preparing the reagents according to the method for later use;
(2) respectively arranging a standard substance hole and a sample hole to be detected, adding 100 mu l of the standard substance or the sample to be detected into each hole, slightly shaking and uniformly mixing, covering a plate, and then incubating for 2h at 37 ℃;
(3) discarding the liquid and spin-drying;
(4) adding biotin labeled antibody working solution into each hole, covering a new plate, and incubating for 1h at 37 ℃;
(5) discarding liquid in the hole, spin-drying, washing and spin-drying again;
(6) adding horseradish peroxidase labeled avidin working solution into each hole, covering a new plate, and incubating for 1h at 37 ℃;
(7) discarding liquid in the hole, spin-drying, washing and spin-drying again;
(8) adding substrate solution into each well, and developing at 37 deg.C in dark for 30min;
(9) adding a termination solution into each hole to terminate the reaction; the optical density (OD value) of each well was measured at a wavelength of 450nm with a microplate reader within five minutes.
In summary, due to the adoption of the technical scheme, the invention has the beneficial effects that:
1. in the invention, the membrane-bound and soluble Sema4A are used as the diagnosis markers of the systemic lupus erythematosus, so that the kit has higher diagnosis efficiency, can be used for evaluating the disease activity and has certain value for evaluating organ damage;
2. the systemic lupus erythematosus diagnosis marker Sema4A has higher sensitivity to SLE, is beneficial to improving the detection rate of early stage of diseases by combining detection with the autoantibody, and solves the problems of low index sensitivity and easy detection omission of SLE diagnosis in the prior art, so that the application of the diagnosis marker of the invention has very important significance for early diagnosis of systemic lupus erythematosus which is difficult to diagnose due to atypical early clinical performance;
3. the membrane-bound type and soluble type Sema4A can be used for differential diagnosis of systemic lupus erythematosus and rheumatoid arthritis, and because the membrane-bound type and soluble type Sema4A of systemic lupus erythematosus patients are obviously higher than healthy people, and the membrane-bound type and soluble type Sema4A of rheumatoid arthritis patients are obviously lower than healthy people, the two diseases with similar clinical manifestations can be identified;
4. the application of the invention comprises that the detection reagent of Sema4A is adopted for quantitatively detecting the concentration of soluble Sema4A in plasma or the Sema4A antibody is used for detecting the surface membrane combined Sema4A level of peripheral blood cells by flow cytometry, and the two detection methods are adopted to be used independently or together according to different scenes, so that better diagnosis effect can be obtained.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments. It should be understood that the detailed description and specific examples, while indicating embodiments of the invention, are given by way of illustration only, not by way of limitation, i.e., the embodiments described are intended as a selection of the best mode contemplated for carrying out the invention, not as a full mode.
Thus, the following detailed description of the embodiments of the present invention is not intended to limit the scope of the invention as claimed, but is merely representative of selected embodiments of the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments of the present invention without making any creative effort, shall fall within the protection scope of the present invention.
It is noted that relational terms such as "first" and "second," and the like, may be used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. Also, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus. Without further limitation, an element defined by the phrase "comprising a … …" does not exclude the presence of another identical element in a process, method, article, or apparatus that comprises the element.
The features and properties of the present invention are described in further detail below with reference to examples.
Example 1
Flow Cytometry (FCM) analysis of the expression of membrane-bound Sema4A on peripheral blood cells:
(1) Collecting 5ml of peripheral blood sample and placing the peripheral blood sample in an EDTA anticoagulation tube;
(2) Adding the peripheral blood sample into 4 centrifugal tubes of 5ml according to 200 mul per tube, and respectively naming the sample as a No. 1 centrifugal tube, a No. 2 centrifugal tube, a No. 3 centrifugal tube and a No. 4 centrifugal tube;
(3) Adding an anti-human CD100-Alexa 647 antibody, an anti-human CD4-PE antibody and an anti-human CD19-FITC antibody into a No. 1 centrifugal tube, and incubating at room temperature in a dark place for 15min; no. 3 centrifuge tube is provided with isotype control; adding an anti-human Sema4A-PerCP-eFluor 710 antibody, an anti-human CD11c-APC antibody, an anti-human CD4-PE antibody and an anti-human CD19-FITC antibody into a No. 2 centrifugal tube, incubating for 15min at room temperature in a dark place, and setting isotype control in the No. 4 centrifugal tube;
(4) Respectively adding 700 mul of erythrocyte lysate into each centrifuge tube, and placing for 10min in the dark until the erythrocytes are completely lysed;
(5) Adding 2-3 ml PBS into each tube, mixing uniformly, centrifuging for 5min at 1000 r/min, removing supernatant, and repeating twice;
(6) Adding 200 μ l PBS into each tube, mixing, and detecting.
The method is adopted to respectively carry out sampling detection on Systemic Lupus Erythematosus (SLE) patients, rheumatoid Arthritis (RA) patients and healthy people with matched age and gender, and the results are shown in the following table 1:
TABLE 1 Sema4A expression Table on SLE, RA and healthy subjects mDCs
As can be seen from the above table, the concentration of membrane-bound Sema4A in mDCs of SLE patients was significantly higher than that in RA patients (p = 0.000) and healthy patients (p = 0.000). The result shows that the membrane-bound Sema4A can be used for clinical diagnosis of systemic lupus erythematosus and differential diagnosis of rheumatoid arthritis.
Example 2
Enzyme-linked immunosorbent assay (ELISA) detects the concentration of soluble Sema4A in plasma:
(1) Freezing and thawing all reagents in the kit for 30min at room temperature, taking out a plasma sample stored in a refrigerator at minus 80 ℃, standing to room temperature, and centrifuging for later use;
(2) Preparing a reagent: (1) preparing a standard substance: taking a Sema4A antibody standard substance out of the ELISA kit, centrifuging at 10000 r/min for 30 seconds, dissolving with 1ml of sample diluent, repeatedly blowing and beating the bottom of an EP tube by using a gun head to assist the dissolution, and fully and uniformly mixing to obtain a standard substance S7; then, arranging 7 1.5ml Ep tubes (named as S0-S6 respectively) in sequence, adding 250pl of sample diluent respectively, sucking 250ml of S7 standard substance, placing the standard substance in a first Ep tube (S6), lightly blowing, beating and uniformly mixing, sucking 250ml from the S6 into a second Ep tube (S5), lightly blowing, beating and uniformly mixing in the same way, and performing multiple dilution on the standard substance by analogy, wherein S0 is the sample diluent; (2) preparing a washing working solution: the concentrated washing solution is mixed with deionized water according to the ratio of l: diluting by 25 times for later use; (3) preparing a biotin labeled antibody working solution: the biotin labeled antibody fluid was expressed as 1: diluting with 100 times of biotin labeled antibody diluent for later use; (4) preparing a horse radish peroxidase labeled avidin working solution: horse radish peroxidase-labeled avidin was added as 1: diluting 100 times with horse radish peroxidase labeled avidin diluent for later use;
(3) The following operations were performed according to the ELISA instructions:
(1) placing various reagents at room temperature (18-25 deg.C) for balancing for at least 30min, and preparing reagents according to the above method;
(2) respectively arranging a standard substance hole and a sample hole to be detected, adding 100 mu l of the standard substance or the sample to be detected into each hole, slightly shaking and uniformly mixing, covering a plate, and then incubating for 2h at 37 ℃;
(3) discarding the liquid and spin-drying;
(4) adding 100 mul of biotin labeled antibody working solution into each hole, covering a new plate, and incubating for 1h at 37 ℃;
(5) discarding liquid in the holes, spin-drying, washing for 5 times by using an automatic plate washing machine, soaking for 30s each time, and spin-drying at a rate of 200 mul/hole;
(6) adding 100 mul of horse radish peroxidase labeled avidin working solution into each hole, covering a new plate, and incubating for 1h at 37 ℃;
(7) discarding liquid in the holes, spin-drying, washing for 6 times by using an automatic plate washing machine, soaking for 30s each time, and spin-drying at a rate of 200 mul/hole;
(8) adding 90 μ l of substrate solution into each well, and developing at 37 deg.C in dark for 30min;
(9) adding 50 mu l of termination solution into each hole to terminate the reaction; the optical density (OD value) of each well was measured at a wavelength of 450nm with a microplate reader within 5 min.
The method is adopted to respectively carry out sampling detection on Systemic Lupus Erythematosus (SLE) patients, rheumatoid Arthritis (RA) patients and healthy patients, and the results are shown in the following table 2:
TABLE 2 SLE, RA and plasma concentrations of soluble Sema4A in healthy subjects
As can be seen from the table above, the expression of soluble Sema4A in the plasma of SLE patients was significantly higher than that of RA patients (p = 0.000) and healthy ones (p = 0.000). The result shows that the secretory Sema4A can be used for clinical diagnosis of systemic lupus erythematosus and also can be used for differential diagnosis with rheumatoid arthritis.
Example 3
Based on the example 1 and the example 2, the correlation between the Sema4A of the SLE patient and the clinical index is further analyzed according to the Pearson correlation coefficient, and the results show that: the concentration of soluble Sema4A in SLE patients is positively correlated with anti-dsDNA antibody levels (p =0.000,r = 0.742); (2) is negatively correlated with the water averages of C3, C4 and Hb (p =0.001,r = -0.583; (3) the concentration of soluble Sema4A in the plasma of SLE patients who were urine protein positive was significantly higher than that of the negative group (p = 0.029).
It can be seen that Sema4A has a strong correlation with anti-dsDNA antibodies, the maturation marker currently used for diagnosing SLE, and therefore can be used as a marker for assessing SLE disease activity (negatively correlated with C3 and C4), and has a certain value for assessing blood system damage (negatively correlated with Hb levels) and kidney damage (the concentration of soluble Sema4A in plasma of SLE patients who are urine protein positive is significantly higher than that in urine protein negative group).
Example 4
On the basis of the example 1 and the example 2, an ROC curve is established to evaluate the diagnosis efficacy of the soluble Sema4A on the SLE through SPSS analysis software, and the area under the curve (AUC) is calculated to be 0.799, the corresponding sensitivity is 0.833, the specificity is 0.696, and the Youden index is 0.529; the ROC curve evaluated the diagnostic efficacy of membrane-bound Sema4A on sleds cells for SLE, calculated as AUC 0.830, corresponding to a sensitivity of 0.864, a specificity of 0.733 and a youden index of 0.597.
Example 5
The diagnostic efficacy of Sema4A was compared to the existing markers on the basis of example 1 and example 2, as shown in table 3 below:
TABLE 3 comparative table of diagnostic efficacy
The Area AUC (Area Under cut) Under the calculated ROC Curve of the marker Sema4A is respectively as follows: soluble form 0.799, membrane bound form 0.830. Compared to other markers available, sema4A has a higher AUC value, second only to ANA. Indicating that Sema4A has better diagnostic efficacy.
Example 6
Based on examples 1 and 2, the sensitivity and specificity of Sema4A was compared to existing markers as shown in table 4 below:
TABLE 4 comparative table of sensitivity and specificity
The anti-dsDNA antibody and the anti-Sm antibody are the indexes with the highest specificity currently used for SLE diagnosis, but the sensitivity of the anti-dsDNA antibody and the anti-Sm antibody is very low, and the missed detection is easily caused. The Sema4A sensitivity of the invention is more than 80% (ROC curve analysis result), which is much higher than the anti-dsDNA antibody and anti-Sm antibody, and can make up the delay of SLE diagnosis and treatment caused by insufficient sensitivity.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents and improvements made within the spirit and principle of the present invention are intended to be included within the scope of the present invention.
Sequence listing
<110> Chuanbei medical college
<120> diagnostic marker for systemic lupus erythematosus and application thereof
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 761
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 1
Met Ala Leu Pro Ala Leu Gly Leu Asp Pro Trp Ser Leu Leu Gly Leu
1 5 10 15
Phe Leu Phe Gln Leu Leu Gln Leu Leu Leu Pro Thr Thr Thr Ala Gly
20 25 30
Gly Gly Gly Gln Gly Pro Met Pro Arg Val Arg Tyr Tyr Ala Gly Asp
35 40 45
Glu Arg Arg Ala Leu Ser Phe Phe His Gln Lys Gly Leu Gln Asp Phe
50 55 60
Asp Thr Leu Leu Leu Ser Gly Asp Gly Asn Thr Leu Tyr Val Gly Ala
65 70 75 80
Arg Glu Ala Ile Leu Ala Leu Asp Ile Gln Asp Pro Gly Val Pro Arg
85 90 95
Leu Lys Asn Met Ile Pro Trp Pro Ala Ser Asp Arg Lys Lys Ser Glu
100 105 110
Cys Ala Phe Lys Lys Lys Ser Asn Glu Thr Gln Cys Phe Asn Phe Ile
115 120 125
Arg Val Leu Val Ser Tyr Asn Val Thr His Leu Tyr Thr Cys Gly Thr
130 135 140
Phe Ala Phe Ser Pro Ala Cys Thr Phe Ile Glu Leu Gln Asp Ser Tyr
145 150 155 160
Leu Leu Pro Ile Ser Glu Asp Lys Val Met Glu Gly Lys Gly Gln Ser
165 170 175
Pro Phe Asp Pro Ala His Lys His Thr Ala Val Leu Val Asp Gly Met
180 185 190
Leu Tyr Ser Gly Thr Met Asn Asn Phe Leu Gly Ser Glu Pro Ile Leu
195 200 205
Met Arg Thr Leu Gly Ser Gln Pro Val Leu Lys Thr Asp Asn Phe Leu
210 215 220
Arg Trp Leu His His Asp Ala Ser Phe Val Ala Ala Ile Pro Ser Thr
225 230 235 240
Gln Val Val Tyr Phe Phe Phe Glu Glu Thr Ala Ser Glu Phe Asp Phe
245 250 255
Phe Glu Arg Leu His Thr Ser Arg Val Ala Arg Val Cys Lys Asn Asp
260 265 270
Val Gly Gly Glu Lys Leu Leu Gln Lys Lys Trp Thr Thr Phe Leu Lys
275 280 285
Ala Gln Leu Leu Cys Thr Gln Pro Gly Gln Leu Pro Phe Asn Val Ile
290 295 300
Arg His Ala Val Leu Leu Pro Ala Asp Ser Pro Thr Ala Pro His Ile
305 310 315 320
Tyr Ala Val Phe Thr Ser Gln Trp Gln Val Gly Gly Thr Arg Ser Ser
325 330 335
Ala Val Cys Ala Phe Ser Leu Leu Asp Ile Glu Arg Val Phe Lys Gly
340 345 350
Lys Tyr Lys Glu Leu Asn Lys Glu Thr Ser Arg Trp Thr Thr Tyr Arg
355 360 365
Gly Pro Glu Thr Asn Pro Arg Pro Gly Ser Cys Ser Val Gly Pro Ser
370 375 380
Ser Asp Lys Ala Leu Thr Phe Met Lys Asp His Phe Leu Met Asp Glu
385 390 395 400
Gln Val Val Gly Thr Pro Leu Leu Val Lys Ser Gly Val Glu Tyr Thr
405 410 415
Arg Leu Ala Val Glu Thr Ala Gln Gly Leu Asp Gly His Ser His Leu
420 425 430
Val Met Tyr Leu Gly Thr Thr Thr Gly Ser Leu His Lys Ala Val Val
435 440 445
Ser Gly Asp Ser Ser Ala His Leu Val Glu Glu Ile Gln Leu Phe Pro
450 455 460
Asp Pro Glu Pro Val Arg Asn Leu Gln Leu Ala Pro Thr Gln Gly Ala
465 470 475 480
Val Phe Val Gly Phe Ser Gly Gly Val Trp Arg Val Pro Arg Ala Asn
485 490 495
Cys Ser Val Tyr Glu Ser Cys Val Asp Cys Val Leu Ala Arg Asp Pro
500 505 510
His Cys Ala Trp Asp Pro Glu Ser Arg Thr Cys Cys Leu Leu Ser Ala
515 520 525
Pro Asn Leu Asn Ser Trp Lys Gln Asp Met Glu Arg Gly Asn Pro Glu
530 535 540
Trp Ala Cys Ala Ser Gly Pro Met Ser Arg Ser Leu Arg Pro Gln Ser
545 550 555 560
Arg Pro Gln Ile Ile Lys Glu Val Leu Ala Val Pro Asn Ser Ile Leu
565 570 575
Glu Leu Pro Cys Pro His Leu Ser Ala Leu Ala Ser Tyr Tyr Trp Ser
580 585 590
His Gly Pro Ala Ala Val Pro Glu Ala Ser Ser Thr Val Tyr Asn Gly
595 600 605
Ser Leu Leu Leu Ile Val Gln Asp Gly Val Gly Gly Leu Tyr Gln Cys
610 615 620
Trp Ala Thr Glu Asn Gly Phe Ser Tyr Pro Val Ile Ser Tyr Trp Val
625 630 635 640
Asp Ser Gln Asp Gln Thr Leu Ala Leu Asp Pro Glu Leu Ala Gly Ile
645 650 655
Pro Arg Glu His Val Lys Val Pro Leu Thr Arg Val Ser Gly Gly Ala
660 665 670
Ala Leu Ala Ala Gln Gln Ser Tyr Trp Pro His Phe Val Thr Val Thr
675 680 685
Val Leu Phe Ala Leu Val Leu Ser Gly Ala Leu Ile Ile Leu Val Ala
690 695 700
Ser Pro Leu Arg Ala Leu Arg Ala Arg Gly Lys Val Gln Gly Cys Glu
705 710 715 720
Thr Leu Arg Pro Gly Glu Lys Ala Pro Leu Ser Arg Glu Gln His Leu
725 730 735
Gln Ser Pro Lys Glu Cys Arg Thr Ser Ala Ser Asp Val Asp Ala Asp
740 745 750
Asn Asn Cys Leu Gly Thr Glu Val Ala
755 760
<210> 2
<211> 629
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 2
Met Ile Pro Trp Pro Ala Ser Asp Arg Lys Lys Ser Glu Cys Ala Phe
1 5 10 15
Lys Lys Lys Ser Asn Glu Glu Leu Gln Asp Ser Tyr Leu Leu Pro Ile
20 25 30
Ser Glu Asp Lys Val Met Glu Gly Lys Gly Gln Ser Pro Phe Asp Pro
35 40 45
Ala His Lys His Thr Ala Val Leu Val Asp Gly Met Leu Tyr Ser Gly
50 55 60
Thr Met Asn Asn Phe Leu Gly Ser Glu Pro Ile Leu Met Arg Thr Leu
65 70 75 80
Gly Ser Gln Pro Val Leu Lys Thr Asp Asn Phe Leu Arg Trp Leu His
85 90 95
His Asp Ala Ser Phe Val Ala Ala Ile Pro Ser Thr Gln Val Val Tyr
100 105 110
Phe Phe Phe Glu Glu Thr Ala Ser Glu Phe Asp Phe Phe Glu Arg Leu
115 120 125
His Thr Ser Arg Val Ala Arg Val Cys Lys Asn Asp Val Gly Gly Glu
130 135 140
Lys Leu Leu Gln Lys Lys Trp Thr Thr Phe Leu Lys Ala Gln Leu Leu
145 150 155 160
Cys Thr Gln Pro Gly Gln Leu Pro Phe Asn Val Ile Arg His Ala Val
165 170 175
Leu Leu Pro Ala Asp Ser Pro Thr Ala Pro His Ile Tyr Ala Val Phe
180 185 190
Thr Ser Gln Trp Gln Val Gly Gly Thr Arg Ser Ser Ala Val Cys Ala
195 200 205
Phe Ser Leu Leu Asp Ile Glu Arg Val Phe Lys Gly Lys Tyr Lys Glu
210 215 220
Leu Asn Lys Glu Thr Ser Arg Trp Thr Thr Tyr Arg Gly Pro Glu Thr
225 230 235 240
Asn Pro Arg Pro Gly Ser Cys Ser Val Gly Pro Ser Ser Asp Lys Ala
245 250 255
Leu Thr Phe Met Lys Asp His Phe Leu Met Asp Glu Gln Val Val Gly
260 265 270
Thr Pro Leu Leu Val Lys Ser Gly Val Glu Tyr Thr Arg Leu Ala Val
275 280 285
Glu Thr Ala Gln Gly Leu Asp Gly His Ser His Leu Val Met Tyr Leu
290 295 300
Gly Thr Thr Thr Gly Ser Leu His Lys Ala Val Val Ser Gly Asp Ser
305 310 315 320
Ser Ala His Leu Val Glu Glu Ile Gln Leu Phe Pro Asp Pro Glu Pro
325 330 335
Val Arg Asn Leu Gln Leu Ala Pro Thr Gln Gly Ala Val Phe Val Gly
340 345 350
Phe Ser Gly Gly Val Trp Arg Val Pro Arg Ala Asn Cys Ser Val Tyr
355 360 365
Glu Ser Cys Val Asp Cys Val Leu Ala Arg Asp Pro His Cys Ala Trp
370 375 380
Asp Pro Glu Ser Arg Thr Cys Cys Leu Leu Ser Ala Pro Asn Leu Asn
385 390 395 400
Ser Trp Lys Gln Asp Met Glu Arg Gly Asn Pro Glu Trp Ala Cys Ala
405 410 415
Ser Gly Pro Met Ser Arg Ser Leu Arg Pro Gln Ser Arg Pro Gln Ile
420 425 430
Ile Lys Glu Val Leu Ala Val Pro Asn Ser Ile Leu Glu Leu Pro Cys
435 440 445
Pro His Leu Ser Ala Leu Ala Ser Tyr Tyr Trp Ser His Gly Pro Ala
450 455 460
Ala Val Pro Glu Ala Ser Ser Thr Val Tyr Asn Gly Ser Leu Leu Leu
465 470 475 480
Ile Val Gln Asp Gly Val Gly Gly Leu Tyr Gln Cys Trp Ala Thr Glu
485 490 495
Asn Gly Phe Ser Tyr Pro Val Ile Ser Tyr Trp Val Asp Ser Gln Asp
500 505 510
Gln Thr Leu Ala Leu Asp Pro Glu Leu Ala Gly Ile Pro Arg Glu His
515 520 525
Val Lys Val Pro Leu Thr Arg Val Ser Gly Gly Ala Ala Leu Ala Ala
530 535 540
Gln Gln Ser Tyr Trp Pro His Phe Val Thr Val Thr Val Leu Phe Ala
545 550 555 560
Leu Val Leu Ser Gly Ala Leu Ile Ile Leu Val Ala Ser Pro Leu Arg
565 570 575
Ala Leu Arg Ala Arg Gly Lys Val Gln Gly Cys Glu Thr Leu Arg Pro
580 585 590
Gly Glu Lys Ala Pro Leu Ser Arg Glu Gln His Leu Gln Ser Pro Lys
595 600 605
Glu Cys Arg Thr Ser Ala Ser Asp Val Asp Ala Asp Asn Asn Cys Leu
610 615 620
Gly Thr Glu Val Ala
625
<210> 3
<211> 662
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 3
Met Ile Pro Trp Pro Ala Ser Asp Arg Lys Lys Ser Glu Cys Ala Phe
1 5 10 15
Lys Lys Lys Ser Asn Glu Thr Gln Cys Phe Asn Phe Ile Arg Val Leu
20 25 30
Val Ser Tyr Asn Val Thr His Leu Tyr Thr Cys Gly Thr Phe Ala Phe
35 40 45
Ser Pro Ala Cys Thr Phe Ile Glu Leu Gln Asp Ser Tyr Leu Leu Pro
50 55 60
Ile Ser Glu Asp Lys Val Met Glu Gly Lys Gly Gln Ser Pro Phe Asp
65 70 75 80
Pro Ala His Lys His Thr Ala Val Leu Val Asp Gly Met Leu Tyr Ser
85 90 95
Gly Thr Met Asn Asn Phe Leu Gly Ser Glu Pro Ile Leu Met Arg Thr
100 105 110
Leu Gly Ser Gln Pro Val Leu Lys Thr Asp Asn Phe Leu Arg Trp Leu
115 120 125
His His Asp Ala Ser Phe Val Ala Ala Ile Pro Ser Thr Gln Val Val
130 135 140
Tyr Phe Phe Phe Glu Glu Thr Ala Ser Glu Phe Asp Phe Phe Glu Arg
145 150 155 160
Leu His Thr Ser Arg Val Ala Arg Val Cys Lys Asn Asp Val Gly Gly
165 170 175
Glu Lys Leu Leu Gln Lys Lys Trp Thr Thr Phe Leu Lys Ala Gln Leu
180 185 190
Leu Cys Thr Gln Pro Gly Gln Leu Pro Phe Asn Val Ile Arg His Ala
195 200 205
Val Leu Leu Pro Ala Asp Ser Pro Thr Ala Pro His Ile Tyr Ala Val
210 215 220
Phe Thr Ser Gln Trp Gln Val Gly Gly Thr Arg Ser Ser Ala Val Cys
225 230 235 240
Ala Phe Ser Leu Leu Asp Ile Glu Arg Val Phe Lys Gly Lys Tyr Lys
245 250 255
Glu Leu Asn Lys Glu Thr Ser Arg Trp Thr Thr Tyr Arg Gly Pro Glu
260 265 270
Thr Asn Pro Arg Pro Gly Ser Cys Ser Val Gly Pro Ser Ser Asp Lys
275 280 285
Ala Leu Thr Phe Met Lys Asp His Phe Leu Met Asp Glu Gln Val Val
290 295 300
Gly Thr Pro Leu Leu Val Lys Ser Gly Val Glu Tyr Thr Arg Leu Ala
305 310 315 320
Val Glu Thr Ala Gln Gly Leu Asp Gly His Ser His Leu Val Met Tyr
325 330 335
Leu Gly Thr Thr Thr Gly Ser Leu His Lys Ala Val Val Ser Gly Asp
340 345 350
Ser Ser Ala His Leu Val Glu Glu Ile Gln Leu Phe Pro Asp Pro Glu
355 360 365
Pro Val Arg Asn Leu Gln Leu Ala Pro Thr Gln Gly Ala Val Phe Val
370 375 380
Gly Phe Ser Gly Gly Val Trp Arg Val Pro Arg Ala Asn Cys Ser Val
385 390 395 400
Tyr Glu Ser Cys Val Asp Cys Val Leu Ala Arg Asp Pro His Cys Ala
405 410 415
Trp Asp Pro Glu Ser Arg Thr Cys Cys Leu Leu Ser Ala Pro Asn Leu
420 425 430
Asn Ser Trp Lys Gln Asp Met Glu Arg Gly Asn Pro Glu Trp Ala Cys
435 440 445
Ala Ser Gly Pro Met Ser Arg Ser Leu Arg Pro Gln Ser Arg Pro Gln
450 455 460
Ile Ile Lys Glu Val Leu Ala Val Pro Asn Ser Ile Leu Glu Leu Pro
465 470 475 480
Cys Pro His Leu Ser Ala Leu Ala Ser Tyr Tyr Trp Ser His Gly Pro
485 490 495
Ala Ala Val Pro Glu Ala Ser Ser Thr Val Tyr Asn Gly Ser Leu Leu
500 505 510
Leu Ile Val Gln Asp Gly Val Gly Gly Leu Tyr Gln Cys Trp Ala Thr
515 520 525
Glu Asn Gly Phe Ser Tyr Pro Val Ile Ser Tyr Trp Val Asp Ser Gln
530 535 540
Asp Gln Thr Leu Ala Leu Asp Pro Glu Leu Ala Gly Ile Pro Arg Glu
545 550 555 560
His Val Lys Val Pro Leu Thr Arg Val Ser Gly Gly Ala Ala Leu Ala
565 570 575
Ala Gln Gln Ser Tyr Trp Pro His Phe Val Thr Val Thr Val Leu Phe
580 585 590
Ala Leu Val Leu Ser Gly Ala Leu Ile Ile Leu Val Ala Ser Pro Leu
595 600 605
Arg Ala Leu Arg Ala Arg Gly Lys Val Gln Gly Cys Glu Thr Leu Arg
610 615 620
Pro Gly Glu Lys Ala Pro Leu Ser Arg Glu Gln His Leu Gln Ser Pro
625 630 635 640
Lys Glu Cys Arg Thr Ser Ala Ser Asp Val Asp Ala Asp Asn Asn Cys
645 650 655
Leu Gly Thr Glu Val Ala
660
<210> 4
<211> 592
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 4
Met Glu Gly Lys Gly Gln Ser Pro Phe Asp Pro Ala His Lys His Thr
1 5 10 15
Ala Val Leu Val Asp Gly Met Leu Tyr Ser Gly Thr Met Asn Asn Phe
20 25 30
Leu Gly Ser Glu Pro Ile Leu Met Arg Thr Leu Gly Ser Gln Pro Val
35 40 45
Leu Lys Thr Asp Asn Phe Leu Arg Trp Leu His His Asp Ala Ser Phe
50 55 60
Val Ala Ala Ile Pro Ser Thr Gln Val Val Tyr Phe Phe Phe Glu Glu
65 70 75 80
Thr Ala Ser Glu Phe Asp Phe Phe Glu Arg Leu His Thr Ser Arg Val
85 90 95
Ala Arg Val Cys Lys Asn Asp Val Gly Gly Glu Lys Leu Leu Gln Lys
100 105 110
Lys Trp Thr Thr Phe Leu Lys Ala Gln Leu Leu Cys Thr Gln Pro Gly
115 120 125
Gln Leu Pro Phe Asn Val Ile Arg His Ala Val Leu Leu Pro Ala Asp
130 135 140
Ser Pro Thr Ala Pro His Ile Tyr Ala Val Phe Thr Ser Gln Trp Gln
145 150 155 160
Val Gly Gly Thr Arg Ser Ser Ala Val Cys Ala Phe Ser Leu Leu Asp
165 170 175
Ile Glu Arg Val Phe Lys Gly Lys Tyr Lys Glu Leu Asn Lys Glu Thr
180 185 190
Ser Arg Trp Thr Thr Tyr Arg Gly Pro Glu Thr Asn Pro Arg Pro Gly
195 200 205
Ser Cys Ser Val Gly Pro Ser Ser Asp Lys Ala Leu Thr Phe Met Lys
210 215 220
Asp His Phe Leu Met Asp Glu Gln Val Val Gly Thr Pro Leu Leu Val
225 230 235 240
Lys Ser Gly Val Glu Tyr Thr Arg Leu Ala Val Glu Thr Ala Gln Gly
245 250 255
Leu Asp Gly His Ser His Leu Val Met Tyr Leu Gly Thr Thr Thr Gly
260 265 270
Ser Leu His Lys Ala Val Val Ser Gly Asp Ser Ser Ala His Leu Val
275 280 285
Glu Glu Ile Gln Leu Phe Pro Asp Pro Glu Pro Val Arg Asn Leu Gln
290 295 300
Leu Ala Pro Thr Gln Gly Ala Val Phe Val Gly Phe Ser Gly Gly Val
305 310 315 320
Trp Arg Val Pro Arg Ala Asn Cys Ser Val Tyr Glu Ser Cys Val Asp
325 330 335
Cys Val Leu Ala Arg Asp Pro His Cys Ala Trp Asp Pro Glu Ser Arg
340 345 350
Thr Cys Cys Leu Leu Ser Ala Pro Asn Leu Asn Ser Trp Lys Gln Asp
355 360 365
Met Glu Arg Gly Asn Pro Glu Trp Ala Cys Ala Ser Gly Pro Met Ser
370 375 380
Arg Ser Leu Arg Pro Gln Ser Arg Pro Gln Ile Ile Lys Glu Val Leu
385 390 395 400
Ala Val Pro Asn Ser Ile Leu Glu Leu Pro Cys Pro His Leu Ser Ala
405 410 415
Leu Ala Ser Tyr Tyr Trp Ser His Gly Pro Ala Ala Val Pro Glu Ala
420 425 430
Ser Ser Thr Val Tyr Asn Gly Ser Leu Leu Leu Ile Val Gln Asp Gly
435 440 445
Val Gly Gly Leu Tyr Gln Cys Trp Ala Thr Glu Asn Gly Phe Ser Tyr
450 455 460
Pro Val Ile Ser Tyr Trp Val Asp Ser Gln Asp Gln Thr Leu Ala Leu
465 470 475 480
Asp Pro Glu Leu Ala Gly Ile Pro Arg Glu His Val Lys Val Pro Leu
485 490 495
Thr Arg Val Ser Gly Gly Ala Ala Leu Ala Ala Gln Gln Ser Tyr Trp
500 505 510
Pro His Phe Val Thr Val Thr Val Leu Phe Ala Leu Val Leu Ser Gly
515 520 525
Ala Leu Ile Ile Leu Val Ala Ser Pro Leu Arg Ala Leu Arg Ala Arg
530 535 540
Gly Lys Val Gln Gly Cys Glu Thr Leu Arg Pro Gly Glu Lys Ala Pro
545 550 555 560
Leu Ser Arg Glu Gln His Leu Gln Ser Pro Lys Glu Cys Arg Thr Ser
565 570 575
Ala Ser Asp Val Asp Ala Asp Asn Asn Cys Leu Gly Thr Glu Val Ala
580 585 590
Claims (3)
1. The application of a diagnostic marker of systemic lupus erythematosus in preparing a preparation for distinguishing systemic lupus erythematosus from rheumatoid arthritis is characterized in that the amino acid sequence of the diagnostic marker is shown as SEQ ID NO:1 to SEQ ID NO: 4;
wherein, the membrane bound type and soluble type Sema4A of the systemic lupus erythematosus patient are obviously higher than those of the healthy people, and the membrane bound type and soluble type Sema4A of the rheumatoid arthritis patient are obviously lower than those of the healthy people;
the diagnostic marker is derived from peripheral blood cells.
2. The use of claim 1, wherein the agent comprises an antibody that specifically binds to the diagnostic marker of claim 1.
3. Use of a diagnostic marker for systemic lupus erythematosus in the manufacture of a kit for the differential discrimination between systemic lupus erythematosus and rheumatoid arthritis, the kit comprising an antibody that specifically binds to the diagnostic marker of claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010813838.8A CN112114126B (en) | 2020-08-13 | 2020-08-13 | Diagnostic marker for systemic lupus erythematosus and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010813838.8A CN112114126B (en) | 2020-08-13 | 2020-08-13 | Diagnostic marker for systemic lupus erythematosus and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112114126A CN112114126A (en) | 2020-12-22 |
| CN112114126B true CN112114126B (en) | 2023-03-24 |
Family
ID=73804035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010813838.8A Active CN112114126B (en) | 2020-08-13 | 2020-08-13 | Diagnostic marker for systemic lupus erythematosus and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112114126B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104105706A (en) * | 2011-10-06 | 2014-10-15 | 德克萨斯州立大学董事会 | Anti-human sema4a antibodies useful to treat disease |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011028945A1 (en) * | 2009-09-03 | 2011-03-10 | Genentech, Inc. | Methods for treating, diagnosing, and monitoring rheumatoid arthritis |
| CN102688283B (en) * | 2012-06-15 | 2014-07-02 | 复旦大学附属中山医院 | Chinese traditional medicine capsule for treating lupus erythematosus and preparation method thereof |
-
2020
- 2020-08-13 CN CN202010813838.8A patent/CN112114126B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104105706A (en) * | 2011-10-06 | 2014-10-15 | 德克萨斯州立大学董事会 | Anti-human sema4a antibodies useful to treat disease |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112114126A (en) | 2020-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101960308B (en) | Biomarker for the estimation of acute renal disorder and prognosis of the disorder, and use of the biomarker | |
| CN106405104B (en) | A kind of new cirrhosis or hepatic fibrosis markers | |
| CN103403549B (en) | The Forecasting Methodology of the prognosis of septicemia | |
| CN107056891B (en) | Polypeptide for preparing systemic lupus erythematosus diagnosis product and application thereof | |
| CN108445232B (en) | Application of the NF-L in the detection of neurolues cerebrospinal fluid | |
| CN110018156A (en) | Application of the anti-CarP antibody as systemic lupus erythematosus diagnosis marker | |
| CN112114126B (en) | Diagnostic marker for systemic lupus erythematosus and application thereof | |
| CN115201471A (en) | Marker combination for auxiliary diagnosis of IgA nephropathy, detection kit thereof and renal injury noninvasive detection method | |
| CN111077312B (en) | Application of group of tumor-associated antigens in preparation of cardiac cancer early screening kit | |
| TW202415952A (en) | Device, biomarker group for predicting, assessing or diagnosing preeclampsia risk and use thereof in preparing device for assessing preeclampsia risk | |
| CN112834532A (en) | Application of urine podocyte-derived migration body in predicting early injury of glomerular podocytes | |
| CN106568977A (en) | Applications of sIL-7R in serum in diagnosis of systemic lupus erythenlatosus nephritis | |
| CN111856038A (en) | Application and product of UNC45A in early warning, diagnosis and prognosis evaluation of POP (acute respiratory failure) | |
| CN115015538A (en) | Anti-phospholipid antibody detection kit and application thereof in detection of systemic lupus erythematosus nephritis | |
| CN110687285B (en) | Diagnostic kit and application of MAK16 in preparation of early diagnosis reagent for systemic lupus erythematosus | |
| CN111596068B (en) | Application of Utrophin in early warning, diagnosis and prognosis evaluation of POP (Point of Presence) and product | |
| CN106568938A (en) | Application of DKK1 in serum to diagnosis of systemic lupus erythenlatosus nephritis | |
| CN114578057A (en) | Application of monomer C-reactive protein (mCRP) in preparation of kit and kit | |
| CN106257287B (en) | Growth and differentiation factor 15 assesses the new opplication of the starting cerebral apoplexy of hyperpietic | |
| CN116589576B (en) | Preparation method of anti-HBP monoclonal antibody, monoclonal antibody and application | |
| AU2021105747A4 (en) | Application of diagnostic kit and MAK16 in preparation of reagent for early diagnosis of systemic lupus erythematosus | |
| CN114280300B (en) | Application of urine protein in diagnosis of metabolic liver disease | |
| CN117069857B (en) | Bispecific antibodies to feline NT-proBNP proteins and uses thereof | |
| CN111596067B (en) | Application of ZC3H8 in early warning, diagnosis and prognosis evaluation of POP (Point of Presence) | |
| EP2817636A1 (en) | New method for rapid detection of hepatocyte growth factor in biological fluids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |